Litcius/Paper detail

916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors

J. Desai, B. Markman, M. Millward, E. Garralda, Z.A.A. Wainberg, Martin Gutierrez, James A. Henry, H. Park, Rasha Cosman, Antoine Hollebecque, M.J. Borad, Ali McBride, Linda Favre-Kontula, Ming Zhou, Aidan G. Gilmartin, X. Gong, M. Hidalgo

2025Annals of Oncology7 citationsDOI

Topics & Concepts

MedicineKRASPancreatic ductal adenocarcinomaCancer researchAdenocarcinomaColorectal adenocarcinomaOncologyColorectal cancerSarcomaInternal medicineMutationColon adenocarcinomaCancerPhases of clinical researchChemotherapyPathologyImmunohistochemistryOral CancersMetastasisGemcitabineProtein Kinase Regulation and GTPase SignalingColorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors | Litcius